Skip to content
HowShorted

MADRIGAL PHARMACEUTICALS, INC. short interest in 2022

In 2022, MADRIGAL PHARMACEUTICALS, INC.'s disclosed short interest ran from 8.75% of shares outstanding on 14 Jan 2022 to 6.54% on 30 Dec 2022, a change of -2.21 percentage points. The year's high was 13.87% on 15 Dec 2022 and its low 6.54% on 30 Dec 2022, averaging 10.08% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.90 days on 31 Mar 2022. Full history: MADRIGAL PHARMACEUTICALS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for MADRIGAL PHARMACEUTICALS, INC. in 2022

2022 in figures

Start of year
8.75% (14 Jan 2022)
End of year
6.54% (30 Dec 2022)
Change
-2.21 pp
High
13.87% (15 Dec 2022)
Low
6.54% (30 Dec 2022)
Average
10.08%
Highest days to cover
11.90 (31 Mar 2022)
SEC filings marked
8

Every report in 2022

MADRIGAL PHARMACEUTICALS, INC. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20228.75%8.65
31 Jan 202210.49%5.27
15 Feb 202211.77%5.72
28 Feb 202211.60%9.6310-K filed, results (8-K)
15 Mar 202211.63%11.59
31 Mar 202210.59%11.90
14 Apr 202210.00%8.17
29 Apr 202210.19%10.24
13 May 20229.88%5.9610-Q filed, results (8-K)
31 May 20229.33%10.84
15 Jun 20229.68%9.61
30 Jun 20229.45%7.89
15 Jul 20229.04%8.46
29 Jul 20229.38%10.09
15 Aug 20229.00%8.0610-Q filed, results (8-K)
31 Aug 20228.60%8.49
15 Sep 20228.73%6.50
30 Sep 20228.93%5.79
14 Oct 20229.06%5.21
31 Oct 202210.66%6.83
15 Nov 202212.14%7.8910-Q filed, results (8-K)
30 Nov 202212.66%7.70
15 Dec 202213.87%5.20
30 Dec 20226.54%1.00

See also: MADRIGAL PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.